Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan claims to be first to file patent challenge over Zytiga
The lawsuit has been filed in the United States District Court for the District of New Jersey. Mylan claims to be one of the first to have filed
The lawsuit has been filed in the United States District Court for the District of New Jersey. Mylan claims to be one of the first to have filed
Developed based on recent scientific advances, the nutritional supplements are Renew 180, Clear Ear Complex and Eye Pressure Complex. Botanic Gardens Indiana president Tim Cleland said: "Scientific breakthroughs
The NMDA receptor helps in the transfer of electrical signals between neurons in the brain and in the spinal column. Initial results from the company’s completed single ascending
Octreotide capsules, an oral drug, are indicated for the maintenance therapy of adult patients with acromegaly. The agency has assigned a Prescription Drug User Fee Act (PDUFA) date
Conducted in collaboration with the University of Halle as sponsor and with the participation of two large leukemia study groups in Germany, the trial is aimed at evaluating
The agency has assigned a Prescription Drug User Fee Act (PDUFA) action date of 10 April 2016 for BromSite, which has a long patent life extending to August
The agency has assigned a Prescription Drug User Fee Act (PDUFA) goal date of 01 April 2016 for a decision on this NDA and it reflects a Standard
The acquisition now expands the company’s suite of maternal health business and adds improved commercial capabilities as well as future growth opportunities to its portfolio. Currently, CBR’s storage
The contract with the Biomedical Advanced Research and Development Authority (BARDA) will fund activities related to current Good Manufacturing Practice (cGMP) manufacturing of a drug product and a
Envarsus XR, which received marketing authorization from the FDA on 10 July 2015, is indicated for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus